Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Selected to Present TOTUM-854\u2019s Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Valbiotis"},{"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Reveals Positive TOTUM\u2022854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Valbiotis"}]

Valbiotis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting

Details:

The results, obtained in vivo on models predictive of hypertension in humans, showed that TOTUM•854 is effective in preventing hypertension.

Lead Product(s): TOTUM•854

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM•854

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: University of Avignon

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 12, 2021

ASK
US

Upload
your Pipeline Activity

Valbiotis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

VALBIOTIS Selected to Present TOTUM-854’s Results

Details:

Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Riom R&D platform.

Lead Product(s): TOTUM-854

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-854

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: University of Avignon

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY